title: Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden.
abstract: Antiphospholipid antibodies are associated with a spectrum of pregnancy complications, including preeclampsia and small for gestational age (SGA) fetuses. We sought to assess anticardiolipin and anti-beta2-glycoprotein I (anti-beta2-GPI) IgG and IgM antibody prevalence and the relationship of these antibodies to pregnancy complications in women with the Factor V Leiden (FVL) mutation. The study comprised a secondary analysis of a multicenter, prospective observational study of FVL prevalence among 5188 asymptomatic pregnant women. A subset of 362 women (117 FVL heterozygotes, 245 matched controls) had serum collected at the time of the original study and underwent serum analysis for anticardiolipin and anti-beta2-GPI IgG and IgM as a part of this analysis. The primary outcome was preeclampsia and/or SGA (<10%). The overall prevalence of anticardiolipin and anti-beta2-GPI IgG and IgM antibodies was low and did not vary with FVL status. Forty-seven women (13.0%) developed preeclampsia and/or SGA. There were no differences in primary outcome rates between women with and without aPL antibodies, regardless of FVL mutation status. Among FVL carriers, the presence of antiphospholipid antibodies does not appear to contribute to adverse pregnancy outcome.
authors.affiliation: Department of Obstetrics and Gynecology, University of Utah, 30N 1900E, Room 2B200, Salt Lake City, UT 84132, USA. tracy.manuck@hsc.utah.edu
authors.forename: Tracy
authors.initials: T
authors.lastname: Manuck
authors.forename: D Ware
authors.initials: DW
authors.lastname: Branch
authors.forename: Yinglei
authors.initials: Y
authors.lastname: Lai
authors.forename: Baha
authors.initials: B
authors.lastname: Sibai
authors.forename: Catherine Y
authors.initials: CY
authors.lastname: Spong
authors.forename: George
authors.initials: G
authors.lastname: Wendel
authors.forename: Katharine
authors.initials: K
authors.lastname: Wenstrom
authors.forename: Philip
authors.initials: P
authors.lastname: Samuels
authors.forename: Steve N
authors.initials: SN
authors.lastname: Caritis
authors.forename: Yoram
authors.initials: Y
authors.lastname: Sorokin
authors.forename: Menachem
authors.initials: M
authors.lastname: Miodovnik
authors.forename: Mary J
authors.initials: MJ
authors.lastname: O'Sullivan
authors.forename: Deborah
authors.initials: D
authors.lastname: Conway
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Wapner
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000097:blood; D002308:Cardiolipins / Q000276:immunology; D004252:DNA Mutational Analysis; D005165:Factor V / Q000235:genetics*; D005260:Female; D005317:Fetal Growth Retardation / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology* / Q000503:physiopathology; D006579:Heterozygote; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D009154:Mutation / Q000235:genetics; D011225:Pre-Eclampsia / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology* / Q000503:physiopathology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D053482:beta 2-Glycoprotein I / Q000276:immunology
chemical_list: D017152:Antibodies, Antiphospholipid; D002308:Cardiolipins; D007075:Immunoglobulin M; D053482:beta 2-Glycoprotein I; C095381:factor V Leiden; D005165:Factor V